Arsenic-based therapy benefits leukemia patients.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D010087:Oxides / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide